Vebeglogene autotemcel
Alternative Names: Beta-globin lentiviral vector transduced autologous HSCs - Lantu BiopharmaLatest Information Update: 29 Jul 2024
Price :
$50 *
At a glance
- Originator Lantu Biopharma
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Beta-thalassaemia
Most Recent Events
- 11 May 2024 Phase-I/II clinical trials in Beta-thalassaemia in China (IV) (NCT06308159)
- 13 Mar 2024 Lantu Biopharma plans a phase I/II trial for Beta-thalassemia (IV, Infusion) in April 2024 (NCT06308159)
- 13 Mar 2024 Preclinical trials in Beta-thalassaemia in China (IV) before March 2024